DelveInsight’s, “TCR Therapy Pipeline Insight 2023” report provides comprehensive insights about 30+ companies and 100+ pipeline drugs in the TCR Therapy pipeline landscape. It covers the TCR Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the TCR Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the TCR Therapy Pipeline Report

• DelveInsight’s TCR Therapy pipeline report depicts a robust space with 30+ active players working to develop 100+ pipeline therapies for TCR Therapy treatment.
• The leading companies working in the TCR Therapy Market include Immunocore, GlaxoSmithKline, Altor BioScience Corporation, Immatics, Immunocore, SCG Cell Therapy, Baudax Bio, TScan Therapeutics, 2seventy bio, Treadwell Therapeutics, T-Knife, Triumvira, Abata Therapeutics, Affini-T Therapeutics, Triumvira, Lion TCR, Poseida Therapeutics, Athenex, Inc., Adaptimmune, Neogene Therapeutics, Alaunos Therapeutics, MediGene AG, Zelluna Immunotherapy, and others.
• Promising TCR Therapy Pipeline Therapies in the various stages of development include tumor-specific TCR-T cells, Interleukin-2, VX-121/TEZ/D-IVA, ELX/TEZ/IVA, and others.
• October 2023: TScan Therapeutics Inc. announced a study of Phase 1 clinical trials for TSC-204-A0201. TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the safety and preliminary efficacy of single and repeat dose regimens of TCR’Ts as monotherapies and as T-Plex combinations after lymphodepleting chemotherapy in participants with locally advanced, metastatic solid tumors disease.
• September 2023: Immatics US Inc. announced a study of Phase 1 clinical trials for IMA201 Product. The study purpose is to establish the safety and tolerability of IMA201 in patients with solid tumors that express melanoma-associated antigen 4 and/or 8 (MAGEA4/8). Patients will be closely monitored for safety and for a total of 3 years post IMA201 infusion.
• September 2023: Fred Hutchinson Cancer Center announced a study of Phase 1 clinical trials for Cyclophosphamide, Fludarabine and Bendamustine. This phase I trial evaluates the side effects and best dose of mesothelin-specific T-cells (FH-TCR-Tᴍsʟɴ) in treating patients with pancreatic ductal adenocarcinoma that has spread to other places in the body (metastatic). Chemotherapy drugs, such as cyclophosphamide and fludarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading, and may help increase the efficacy from the infused T cells.
• September 2023: Guangzhou FineImmune Biotechnology Co., Ltd announced a study of Phase 1 clinical trials for Interleukin-2 and tumor-specific TCR-T cells. The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells in the treatment of advanced Solid Tumor. The secondary purpose of this study is to preliminarily showed the effect of TCR-T cells in the treatment of advanced Solid Tumor.

 

Request a sample and discover the recent advances in TCR Therapy Treatment Drugs @ TCR Therapy Pipeline Report

 

In the TCR Therapy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TCR Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

TCR Therapy Overview

The T-cell receptor (TCR) is a molecule found on the surface of T cells, or T lymphocytes, that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules. The binding between TCR and antigen peptides is of relatively low affinity and is degenerate, that is, many TCRs recognize the same antigen peptide and many antigen peptides are recognized by the same TCR. The TCR is composed of two different protein chains (that is, it is a heterodimer).

 

Find out more about TCR Therapy Therapeutics Assessment @ TCR Therapy Preclinical and Discovery Stage Products

 

TCR Therapy Emerging Drugs Profile

• IMC F106C: Immunocore
• GSK 3377794: GlaxoSmithKline
• MDG 1011: MediGene AG
• TSC-100: TScan Therapeutics

 

TCR Therapy Pipeline Therapeutics Assessment

There are approx. 30+ key companies which are developing the therapies for TCR Therapy. The TCR Therapy companies which have their TCR Therapy drug candidates in the most advanced stage, i.e. Phase III include, Immunocore.

 

DelveInsight’s TCR Therapy Pipeline Report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

TCR Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

 

TCR Therapy Pipeline Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Learn more about the emerging TCR Therapy Pipeline Therapies @ TCR Therapy Clinical Trials Assessment

 

Scope of the TCR Therapy Pipeline Report

• Coverage- Global
• TCR Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• TCR Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• TCR Therapy Companies- Immunocore, GlaxoSmithKline, Altor BioScience Corporation, Immatics, Immunocore, SCG Cell Therapy, Baudax Bio, TScan Therapeutics, 2seventy bio, Treadwell Therapeutics, T-Knife, Triumvira, Abata Therapeutics, Affini-T Therapeutics, Triumvira, Lion TCR, Poseida Therapeutics, Athenex, Inc., Adaptimmune, Neogene Therapeutics, Alaunos Therapeutics, MediGene AG, Zelluna Immunotherapy, and others.
• TCR Therapy Pipeline Therapies- tumor-specific TCR-T cells, Interleukin-2, VX-121/TEZ/D-IVA, ELX/TEZ/IVA, and others.

 

Dive deep into rich insights for new drugs for TCR Therapy Treatment, Visit @ TCR Therapy Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. TCR-Therapy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. TCR-Therapy – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. IMC F106C: Immunocore
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. GSK 3377794: GlaxoSmithKline
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. TSC-100: TScan Therapeutics
15. Drug profiles in the detailed report…..
16. Inactive Products
17. TCR-Therapy Key Companies
18. TCR-Therapy Key Products
19. TCR-Therapy- Unmet Needs
20. TCR-Therapy- Market Drivers and Barriers
21. TCR-Therapy- Future Perspectives and Conclusion
22. TCR-Therapy Analyst Views
23. TCR-Therapy Key Companies
24. Appendix

 

For further information on the TCR Therapy Pipeline therapeutics, reach out to TCR Therapy Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/major-depressive-disorder-market